Now approved for use beyond 12 months8
The #1 prescribed FDA-approved treatment for new GA patients12*

*Based on Symphony data from 3/24-1/25. May not represent entire patient population.

READ PRESS RELEASE

For US Healthcare Professionals Only IzervayECP.com Full Prescribing Information References
For US Healthcare
Professionals Only

DETECT GA BEFORE YOUR PATIENTS DO

Keep geographic atrophy (GA) on your radar, because by the time it’s obvious…the damage is done.1,2

GA is a relentless condition that can lead to irreversible vision loss1,3

In just 2.5 years,GA can progress to the central fovea4*

In 1.6 years,~67% of patients with bilateral GA lose the ability to drive5†

In 2 years,~50% of patients with GA experience 10‑letter loss6‡

What may be happening to the retina and your patient's vision7

What may be happening to the retina

What may be happening to your patient's vision7

Some loss of peripheral, low‑light vision

Loss of peripheral, low‑light vision

Loss of peripheral, low‑light vision; patches of central vision loss

Loss of central vision

Some loss of peripheral, low‑light vision

Loss of peripheral, low‑light vision

Loss of peripheral, low‑light vision; patches of central vision loss

Loss of central vision

Representation of vision loss for illustrative purposes only.

*Progression from noncentral to central GA was estimated from 397 AREDS participants in which GA was initially diagnosed during follow-up with no history of neovascularization.4

†Retrospective cohort analysis of an EMR database in the United Kingdom, including 1901 patients with bilateral GA. 1.6 years represents the median (range: 0.7-2.7 years).5

‡Analysis of the Chroma, Spectri, and Proxima A trials, including 2006 patients with GA.6

AREDS=Age-Related Eye Disease Study; EMR=electronic medical record.

Dr. Jeffry Gerson

Make the search for GA routine

Dr. Jeffry Gerson explains how his mindset about GA has evolved and what he’s doing to detect it early.

Search The Scans

Look beneath the surface with multimodal imaging.

Assess Progression

Evaluate risk factors that elevate treatment urgency.

Act Early

A prompt referral for IZERVAY can make a significant difference.8

IMPORTANT SAFETY INFORMATION AND INDICATION

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

CONTRAINDICATIONS

IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

CONTRAINDICATIONS

IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Neovascular AMD

  • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.

Increase in Intraocular Pressure

  • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATIONS

IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Neovascular AMD

  • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.

Increase in Intraocular Pressure

  • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information.

Images courtesy of Heidelberg Engineering, Dr. Julie Rodman, and Dr. Mohammad Rafieetary.